Archived explainer. For the current picture see today's GRAL page.
GRAIL INC EQUITY Equity (GRAL) is up +33.68% in the latest session. Our newswire has captured 5 stories on GRAL across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
GRAIL Inc. (NASDAQ:GRAL) surged 33.68% to $107.97 in Monday’s session, marking one of its most significant moves in over a year. The rally was driven by anticipation of an upcoming FDA advisory panel meeting on September 23, which will review the company’s application for approval of its Galleri cancer detection test. The release of FDA briefing documents and the regulatory catalyst have lifted investor sentiment, pushing the stock above all analyst price targets.
The stock’s sharp rise came ahead of the scheduled FDA review by the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee. The meeting is seen as a critical step toward potential regulatory approval for Grail’s Galleri test, a multi-cancer early detection tool. The stock’s performance was further supported by positive analysis from a ratings upgrade and reports highlighting the test’s high accuracy and low false positives as outlined in FDA documents. The rally occurred despite recent insider sales by the CEO and CFO, which took place in late August.
Over the last eight sessions, GRAL has risen 39.7% from $77.56 to $108.38. The stock closed Monday at $107.97, just below its 52-week high of $118.84. The move was accompanied by 20 fresh 52-week highs printed on the session. Despite the optimism, the company remains unprofitable with a trailing twelve-month (TTM) net margin of -236.9% and an EPS of -9.75. The stock’s beta of 3.25 indicates high volatility. In the last 90 days, insiders have sold $1.1 million worth of shares, with no insider purchases recorded.
The FDA advisory panel meeting on September 23 will be a key event to monitor. The outcome could significantly influence the stock’s trajectory. Investors should also track the breadth of analyst coverage and any follow-up statements from the company following the panel’s decision.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet on Sept. 23 to discuss Grail’s application seeking approval of its cancer detection test.
Menlo Park, September 21, 2026, 15:13 (EDT) Shares of GRAIL, Inc. (NASDAQ:GRAL) surged 34.7% to $108.78 by 15:09 EDT Monday. The move came two sessions before a scheduled FDA advisory-panel review. The stock now exceeds the highest current analyst target in the comparison below. Investors are assigning approval value before regulators have even voted. Volume…
Grail (GRAL) jumps 30% as FDA briefing boosts Galleri cancer test hopes. Read the latest analysis on the stock here.
GRAIL stock was up on Monday ahead of a review from the FDA for the company’s cancer blood test.
Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.
More on GRAL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GRAL move explainers: 2026-09-22 · 2026-09-21 · 2026-08-06